Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in presymptomatic Type 1 Diabetes
NCT07683026Phase 2Not yet recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Aug 2026
- Primary completion
- Sep 2032
- Countries
- 1
01
Overview
A Phase 2 trial of golimumab in type 1 diabetes mellitus (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
golimumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07683026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683026.